Clinical Trial Detail

NCT ID NCT04093167
Title Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Canadian Cancer Trials Group
Indications

lung non-squamous non-small cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

Additional content available in CKB BOOST